

Ref. No: 1234  
Date: 01/10/24  
Subject: New biologic and targeted medications within dermatology

## REQUEST

I am analysing the usage of new biologic and targeted medications within dermatology medicine. Could you please answer the following question:

How many patients were treated in September 2024 (or latest available month) by the Dermatology department with the following drugs:

- Abrocitinib (Cibinqo)
- Baricitinib (Olumiant)
- Dupilumab (Dupixent)
- Lebrikizumab (Ebglyss)
- Omalizumab (Xolair)
- Tralokinumab (Adtralza)
- Upadacitinib (Rinvoq)

## RESPONSE

Mersey and West Lancashire Trust.

- Abrocitinib (Cibinqo) - 0
- Baricitinib (Olumiant) - 8
- Dupilumab (Dupixent) - 20
- Lebrikizumab (Ebglyss) - 0
- Omalizumab (Xolair) - 8
- Tralokinumab (Adtralza) - 1
- Upadacitinib (Rinvoq) - 6